Filing Details
- Accession Number:
- 0000903423-19-000228
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-05-23 18:36:42
- Reporting Period:
- 2019-05-21
- Accepted Time:
- 2019-05-23 18:36:42
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1740547 | Urovant Sciences Ltd. | UROV | () | DE |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1101785 | Viking Global Equities Lp | 55 Railroad Avenue Greenwich CT 06830 | No | No | Yes | No | |
1132625 | Viking Global Performance Llc | 55 Railroad Avenue Greenwich CT 06830 | No | No | Yes | No | |
1133006 | Andreas Ole Halvorsen | 55 Railroad Avenue Greenwich CT 06830 | No | No | Yes | No | |
1413378 | Viking Global Equities Ii Lp | 55 Railroad Avenue Greenwich CT 06830 | No | No | Yes | No | |
1621596 | Ltd. Master Fund Long Viking | 55 Railroad Avenue Greenwich CT 06830 | No | No | Yes | No | |
1621607 | Viking Long Fund Gp Llc | 55 Railroad Avenue Greenwich CT 06830 | No | No | Yes | No | |
1621620 | Ltd. Portfolio Iii Vge | 55 Railroad Avenue Greenwich CT 06830 | No | No | Yes | No | |
1621842 | C. David Ott | 55 Railroad Avenue Greenwich CT 06830 | No | No | Yes | No | |
1711393 | Sharon Rose Shabet | 55 Railroad Avenue Greenwich CT 06830 | No | No | Yes | No | |
1759530 | Ltd. Master Equities Global Viking | 55 Railroad Avenue Greenwich CT 06830 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Shares, Par Value $0.000037453 Per Share | Acquisiton | 2019-05-21 | 9,995 | $8.52 | 22,735,272 | No | 4 | P | Indirect | See Footnotes |
Common Shares, Par Value $0.000037453 Per Share | Acquisiton | 2019-05-22 | 5,033 | $8.06 | 22,740,305 | No | 4 | P | Indirect | See Footnotes |
Common Shares, Par Value $0.000037453 Per Share | Acquisiton | 2019-05-23 | 4,802 | $7.76 | 22,745,107 | No | 4 | P | Indirect | See Footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See Footnotes |
No | 4 | P | Indirect | See Footnotes |
No | 4 | P | Indirect | See Footnotes |
Footnotes
- The transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 ("Rule 10b-18") under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.31 to $8.69, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
- The transaction was a series of open market purchases made under a trading plan established pursuant to Rule 10b5-1 under the Exchange Act and in accordance with the safe harbor of Rule 10b-18
- The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.825 to $8.43, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4.
- The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.645 to $7.98, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4.
- The Reporting Persons do not directly own any shares of common stock (the "Common Shares") of Urovant. The Reporting Persons acquired Roivant Sciences Ltd. ("Roivant") common shares (the "Roivant Common Shares") on December 8, 2015. Roivant directly holds the 22,745,107 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's by-laws, as of the appointment of an independent director (within the meaning of that term under Roivant's by-laws) to Roivant's board of directors effective July 8, 2016, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant.
- O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Long Fund GP LLC ("VLFGP") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP").
- VGI provides managerial services to various investment funds, including Viking Global Equities LP ("VGE"), Viking Global Equities II LP ("VGE II"), VGE III Portfolio Ltd. ("VGE III"), Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund Master Ltd. ("VLFM") and Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund", and together with VGE, VGE II, VGE III, VGEM and VLFM, the "Funds" and the Funds together with VGI, VGP, VLFGP, Opportunities GP, Opportunities Portfolio GP, O. Andreas Halvorsen, David C. Ott and Rose S. Shabet, the "Reporting Persons"). VGP is the general partner of VGE and VGE II and the investment manager of VGE III and VGEM. VLFGP serves as the investment manager of VLFM. Opportunities GP serves as the sole member of Opportunities Portfolio GP. Opportunities Portfolio GP serves as the general partner of Opportunities Fund.
- The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose